Publications by authors named "Christine Ta Thanh Minh"
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Gilles Freyer Noelia Martinez-Jañez Bożena Kukielka-Budny Malgorzata Ulanska Hugues Bourgeois Christine Ta Thanh Minh
Breast
April 2024
Article Synopsis
- Single-agent oral vinorelbine is a recommended treatment for advanced breast cancer that has progressed after hormone therapy, with metronomic dosing potentially offering better safety and efficacy.
- A phase II trial compared metronomic administration (50 mg three times a week) with a weekly schedule (60 mg/m initially, increasing to 80 mg/m) in 163 patients, measuring disease control rate (DCR).
- Results showed DCR was 63.4% for the metronomic group and 72.8% for the weekly group, with the weekly regimen resulting in longer progression-free and overall survival but also more side effects; both schedules are viable options for treatment.
Objective: The study investigated the efficacy and safety of oral vinorelbine-cisplatin (OV-CDDP) and gemcitabine-cisplatin (GEM-CDDP) in patients with squamous non-small cell lung cancer (sq-NSCLC).
Patients And Methods: This was an open-label, prospective, multicenter, international phase II study that enrolled untreated patients with advanced sq-NSCLC. Patients were randomized to receive 3-week cycles of either 60-80 mg/m OV days 1 and 8 in combination with 80 mg/m CDDP day 1 (arm A) or 1250 mg/m GEM days 1 and 8 in combination with 75 mg/m CDDP day 1 (arm B).